Surgical Management of von Hippel-Lindau Disease: Urologic Considerations

Surgical Oncology Clinics of North America

Volumn 18, Issue 1, 2009, Pages 157-174

  Reed, Amanda Beth ^a   Parekh, Dipen J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Carcinoma; Hereditary diseases; Kidney cysts; Nephrectomy; Pheochromocytoma; Renal cell; von Hippel Lindau disease

Indexed keywords

CULLIN; ELONGIN B; ELONGIN C; ENDOTHELIAL CELL GROWTH FACTOR; ERYTHROPOIETIN; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; UBIQUITIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADRENAL TUMOR; ADRENALECTOMY; ANGIOGENESIS; ANGIOMA; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CELL SURVIVAL; CHROMOSOME 3P; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYSTADENOMA; DIALYSIS; DOPPLER FLOWMETRY; FAMILY HISTORY; FOLLOW UP; GENE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC LINKAGE; GENETICS; GERM LAYER; GLUCOSE TRANSPORT; HEMANGIOMA; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; KIDNEY TUMOR; LABORATORY TEST; MINIMALLY INVASIVE SURGERY; MORBIDITY; MORTALITY; MULTIPLE CANCER; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PANCREAS ISLET CELL TUMOR; PHENOTYPIC VARIATION; PHEOCHROMOCYTOMA; PHYSICAL EXAMINATION; PREOPERATIVE EVALUATION; PROTEIN DEGRADATION; RECURRENCE RISK; RENAL REPLACEMENT THERAPY; RETINAL ANGIOMA; REVIEW; RISK REDUCTION; SALVAGE THERAPY; SOLID TUMOR; SOUTHERN BLOTTING; SURGICAL TECHNIQUE; TISSUE GROWTH; TUMOR DIAGNOSIS; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; UROLOGICAL CARE; VASCULARIZATION; VHL GENE; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MASS SCREENING; NEPHRECTOMY; PHEOCHROMOCYTOMA; RISK FACTORS; VON HIPPEL-LINDAU DISEASE;

EID: 56849124658     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.08.005     Document Type: Review

References (115)

1. von Hippel E. Uber eine sehf self seltene erkrankung der netzhaut. Klinische Beobachtungen Arch Opthalmol 59 (1904) 83-106
2. Von Hippel E. Die anatomische Grund lage der von mir beschriebenen 'sehr seltenen Erkrankung der Netzhaut'. Graefes Arch Ophthalmol 79 (1911) 350-377
3. Lindau A. Studien ber kleinbirncysten bau: pathogenese und beziehungen zur angiomatosis retinae. Acta radiol Microbiol Scandinavica 1 Suppl (1926) 1-128
4. Melmon K.L., and Rosen S.W. Lindau's disease. Review of the literature and study of a large kindred. Am J Med 36 (1964) 595-617
5. Maher E.R., Yates J.R., Harries R., et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77 283 (1990) 1151-1163
6. Lonser R.R., Glenn G.M., Walther M., et al. von Hippel-Lindau disease. Lancet 361 9374 (2003) 2059-2067
7. Maher E.R., and Kaelin Jr. W.G. von Hippel-Lindau disease. Medicine (Baltimore) 76 6 (1997) 381-391
8. Neumann H.P. Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa 16 3 (1987) 220-226
9. Walther M.M., Choyke P.L., Glenn G., et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 161 5 (1999) 1475-1479
10. Lund G.O., Fallon B., Curtis M.A., et al. Conservative surgical therapy of localized renal cell carcinoma in von Hippel-Lindau disease. Cancer 74 9 (1994) 2541-2545
11. Herring J.C., Enquist E.G., Chernoff A., et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 165 3 (2001) 777-781
12. Jordan D.K., Patil S.R., Divelbiss J.E., et al. Cytogenetic abnormalities in tumors of patients with von Hippel-Lindau disease. Cancer Genet Cytogenet 42 2 (1989) 227-241
13. Linehan W.M., Lerman M.I., and Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273 7 (1995) 564-570
14. Poston C.D., Jaffe G.S., Lubensky I.A., et al. Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol 153 1 (1995) 22-26
15. In: Wein A.J., Kavoussi L.R., Novick A.C., et al. (Eds). Campbell-Walsh urology. 9th edition (2007), Saunders Elsevier, Philadelphia 3306
16. Solomon D., and Schwartz A. Renal pathology in von Hippel-Lindau disease. Hum Pathol 19 9 (1988) 1072-1079
17. Novick A.C., and Streem S.B. Long-term followup after nephron sparing surgery for renal cell carcinoma in von Hippel-Lindau disease. J Urol 147 6 (1992) 1488-1490
18. Frydenberg M., Malek R.S., and Zincke H. Conservative renal surgery for renal cell carcinoma in von Hippel-Lindau's disease. J Urol 149 3 (1993) 461-464
19. Choyke P.L., Glenn G.M., Walther M.M., et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol 159 6 (1992) 1229-1234
20. Walther M.M., Choyke P.L., Weiss G., et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma. J Urol 153 3 Pt 2 (1995) 913-916
21. Lamiell J.M., Salazar F.G., and Hsia Y.E. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 68 1 (1989) 1-29
22. Chauveau D., Duvic C., Chretien Y., et al. Renal involvement in von Hippel-Lindau disease. Kidney Int 50 3 (1996) 944-951
23. Goldfarb D.A. Nephron-sparing surgery and renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. J Intern Med 243 6 (1998) 563-567
24. Choyke P.L., Glenn G.M., Walther M.M., et al. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 194 3 (1995) 629-642
25. Fill W.L., Lamiell J.M., and Polk N.O. The radiographic manifestations of von Hippel-Lindau disease. Radiology 133 2 (1979) 289-295
26. Choyke P.L., Filling-Katz M.R., Shawker T.H., et al. von Hippel-Lindau disease: radiologic screening for visceral manifestations. Radiology 174 3 Pt 1 (1990) 815-820
27. Murgia A., Martella M., Vinanzi C., et al. Somatic mosaicism in von Hippel-Lindau disease. Hum Mutat 15 1 (2000) 114
28. Sgambati M.T., Stolle C., Choyke P.L., et al. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet 66 1 (2000) 84-91
29. Zbar B., Kishida T., Chen F., et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 8 4 (1996) 348-357
30. Neumann H.P., and Zbar B. Renal cysts, renal cancer and von Hippel-Lindau disease. Kidney Int 51 1 (1997) 16-26
31. Knudson Jr. A.G. Overview: genes that predispose to cancer. Mutat Res 247 2 (1991) 185-190
32. Knudson Jr. A.G. Introduction to the genetics of primary renal tumors in children. Med Pediatr Oncol 21 3 (1993) 193-198
33. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 5112 (1993) 1317-1320
34. Lubensky I.A., Gnarra J.R., Bertheau P., et al. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149 6 (1996) 2089-2094
35. Zbar B., Klausner R., and Linehan W.M. Studying cancer families to identify kidney cancer genes. Annu Rev Med 54 (2003) 217-233
36. Bratslavsky G., Sudarshan S., Neckers L., et al. Pseudohypoxic pathways in renal cell carcinoma. Clin Cancer Res 13 16 (2007) 4667-4671
37. Fishman M.C., and Porter J.A. Pharmaceuticals: a new grammar for drug discovery. Nature 437 7058 (2005) 491-493
38. Cohen A.J., Li F.P., Berg S., et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 301 11 (1979) 592-595
39. Pathak S., Strong L.C., Ferrell R.E., et al. Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells. Science 217 4563 (1982) 939-941
40. Zbar B., Brauch H., Talmadge C., et al. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327 6124 (1987) 721-724
41. Anglard P., Tory K., Brauch H., et al. Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res 51 4 (1991) 1071-1077
42. Latif F., Duh F.M., Gnarra J., et al. von Hippel-Lindau syndrome: cloning and identification of the plasma membrane Ca(++)-transporting ATPase isoform 2 gene that resides in the von Hippel-Lindau gene region. Cancer Res 53 4 (1993) 861-867
43. Stolle C., Glenn G., Zbar B., et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12 6 (1998) 417-423
44. Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91 21 (1994) 9700-9704
45. Herman J.G., Graff J.R., Myohanen S., et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93 18 (1996) 9821-9826
46. Clifford S.C., Prowse A.H., Affara N.A., et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22 3 (1998) 200-209
47. Iliopoulos O., Kibel A., Gray S., et al. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1 8 (1995) 822-826
48. Linehan W.M., Pinto P.A., Srinivasan R., et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 13 2 Pt 2 (2007) 671s-679s
49. Gnarra J.R., Tory K., Weng Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 1 (1994) 85-90
50. Shuin T., Kondo K., Torigoe S., et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54 11 (1994) 2852-2855
51. Knudson Jr. A.G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68 4 (1971) 820-823
52. Maranchie J.K., Afonso A., Albert P.S., et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat 23 1 (2004) 40-46
53. Duan D.R., Pause A., Burgess W.H., et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269 5229 (1995) 1402-1406
54. Kibel A., Iliopoulos O., DeCaprio J.A., et al. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269 5229 (1995) 1444-1446
55. Pause A., Lee S., Worrell R.A., et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 94 6 (1997) 2156-2161
56. Kamura T., Conrad M.N., Yan Q., et al. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 13 22 (1999) 2928-2933
57. Iliopoulos O., Levy A.P., Jiang C., et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 93 20 (1996) 10595-10599
58. Kaelin Jr. W.G., and Maher E.R. The VHL tumour-suppressor gene paradigm. Trends Genet 14 10 (1998) 423-426
59. Kaelin W.G. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harb Symp Quant Biol 70 (2005) 159-166
60. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 6733 (1999) 271-275
61. Epstein A.C., Gleadle J.M., McNeill L.A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 1 (2001) 43-54
62. Ohh M., Park C.W., Ivan M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2 7 (2000) 423-427
63. Isaacs J.S., Jung Y.J., Mole D.R., et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8 2 (2005) 143-153
64. Cockman M.E., Masson N., Mole D.R., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275 33 (2000) 25733-25741
65. Mole D.R., Maxwell P.H., Pugh C.W., et al. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 52 1-2 (2001) 43-47
66. Jaakkola P., Mole D.R., Tian Y.M., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 5516 (2001) 468-472
67. Ivan M., Kondo K., Yang H., et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292 5516 (2001) 464-468
68. Pugh C.W., and Ratcliffe P.J. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 13 1 (2003) 83-89
69. Kamura T., Sato S., Iwai K., et al. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 97 19 (2000) 10430-10435
70. de Paulsen N., Brychzy A., Fournier M.C., et al. Role of transforming growth factor-alpha in von Hippel-Lindau (VHL) (-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci U S A 98 4 (2001) 1387-1392
71. Maranchie J.K., Vasselli J.R., Riss J., et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 3 (2002) 247-255
72. Kondo K., Klco J., Nakamura E., et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 3 (2002) 237-246
73. Kondo K., Kim W.Y., Lechpammer M., et al. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 1 3 (2003) E83
74. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 1 (2006) 16-24
75. Rapisarda A., Uranchimeg B., Sordet O., et al. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64 4 (2004) 1475-1482
76. Isaacs J.S., Jung Y.J., Mimnaugh E.G., et al. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277 33 (2002) 29936-29944
77. Maher E.R., Iselius L., Yates J.R., et al. Von Hippel-Lindau disease: a genetic study. J Med Genet 28 7 (1991) 443-447
78. Neumann H.P., and Wiestler O.D. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337 8749 (1991) 1052-1054
79. Steinbach F., Novick A.C., Zincke H., et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J Urol 153 6 (1995) 1812-1816
80. Martz C.H. von Hippel-Lindau disease: a genetic condition predisposing tumor formation. Oncol Nurs Forum 18 3 (1991) 545-551
81. Horton W.A., Wong V., and Eldridge R. Von Hippel-Lindau disease: clinical and pathological manifestations in nine families with 50 affected members. Arch Intern Med 136 7 (1976) 769-777
82. Glenn G., Choyke P., Zbar B., et al. von Hippel Lindau disease: clinical aspects and molecular genetics. In: Anderson E. (Ed). Problems in urologic surgery: benign and malignant tumors of the kidney (1990), Lippincott, Philadelphia 312-337
83. Filling-Katz M.R., Choyke P.L., Oldfield E., et al. Central nervous system involvement in von Hippel-Lindau disease. Neurology 41 1 (1991) 41-46
84. Neumann H.P., Eggert H.R., Scheremet R., et al. Central nervous system lesions in von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry 55 10 (1992) 898-901
85. Walther M.M., Choyke P.L., Hayes W., et al. Evaluation of color Doppler intraoperative ultrasound in parenchymal sparing renal surgery. J Urol 152 6 Pt 1 (1994) 1984-1987
86. Miller D.L., Choyke P.L., Walther M.M., et al. von Hippel-Lindau disease: inadequacy of angiography for identification of renal cancers. Radiology 179 3 (1991) 833-836
87. Pearson J.C., Weiss J., and Tanagho E.A. A plea for conservation of kidney in renal adenocarcinoma associated with von Hippel-Lindau disease. J Urol 124 6 (1980) 910-912
88. Loughlin K.R., and Gittes R.F. Urological management of patients with von Hippel-Lindau's disease. J Urol 136 4 (1986) 789-791
89. Malek R.S., Omess P.J., Benson Jr. R.C., et al. Renal cell carcinoma in von Hippel-Lindau syndrome. Am J Med 82 2 (1987) 236-238
90. Richard S., Chauveau D., Chretien Y., et al. Renal lesions and pheochromocytoma in von Hippel-Lindau disease. Adv Nephrol Necker Hosp 23 (1994) 1-27
91. Neumann H.P., Bender B.U., Berger D.P., et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol 160 4 (1998) 1248-1254
92. Walther M.M., Lubensky I.A., Venzon D., et al. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol 154 6 (1995) 2010-2014 [discussion: 2014-5]
93. Walther M.M., Thompson N., and Linehan W. Enucleation procedures in patients with multiple hereditary renal tumors. World J Urol 13 4 (1995) 248-250
94. Duffey B.G., Choyke P.L., Glenn G., et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol 172 1 (2004) 63-65
95. Fetner C.D., Barilla D.E., Scott T., et al. Bilateral renal cell carcinoma in von Hippel-Lindau syndrome: treatment with staged bilateral nephrectomy and hemodialysis. J Urol 117 4 (1977) 534-536
96. Levine E., Weigel J.W., and Collins D.L. Diagnosis and management of asymptomatic renal cell carcinomas in von Hippel-Lindau syndrome. Urology 21 2 (1983) 146-150
97. Spencer W.F., Novick A.C., Montie J.E., et al. Surgical treatment of localized renal cell carcinoma in von Hippel-Lindau's disease. J Urol 139 3 (1988) 507-509
98. Goldfarb D.A., Neumann H.P., Penn I., et al. Results of renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Transplantation 64 12 (1997) 1726-1729
99. Roupret M., Hopirtean V., Mejean A., et al. Nephron sparing surgery for renal cell carcinoma and von Hippel-Lindau's disease: a single center experience. J Urol 170 5 (2003) 1752-1755
100. Ploussard G., Droupy S., Ferlicot S., et al. Local recurrence after nephron-sparing surgery in von-Hippel-Lindau disease. Urology 70 3 (2007) 435-439
101. Bratslavsky G., Liu J.J., Ferlicot S., et al. Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol 179 1 (2008) 67-70
102. Magera Jr. J.S., Frank I., Lohse C.M., et al. Analysis of repeat nephron sparing surgery as a treatment option in patients with a solid mass in a renal remnant. J Urol 179 3 (2008) 853-856
103. Patard J.J., Shvarts O., Lam J.S., et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171 6 Pt 1 (2004) 2181-2185 [quiz 2435]
104. Thompson R.H., Leibovich B.C., Lohse C.M., et al. Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol 174 3 (2005) 855-858
105. Kunkle D.A., Egleston B.L., and Uzzo R.G. Excise, ablate or observe: the small renal mass dilemma-a meta-analysis and review. J Urol 179 4 (2008) 1227-1233
106. Aron M., and Gill I.S. Minimally invasive nephron-sparing surgery (MINSS) for renal tumours. Part II: probe ablative therapy. Eur Urol 51 2 (2007) 348-357
107. Mahnken A.H., Gunther R.W., and Tacke J. Radiofrequency ablation of renal tumors. Eur Radiol 14 8 (2004) 1449-1455
108. Walther M.M., Reiter R., Keiser H.R., et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162 3 Pt 1 (1999) 659-664
109. Glenn G.M., Daniel L.N., Choyke P., et al. Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus. Hum Genet 87 2 (1991) 207-210
110. Chen F., Kishida T., Yao M., et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5 1 (1995) 66-75
111. Aprill B.S., Drake III A.J., Lasseter D.H., et al. Silent adrenal nodules in von Hippel-Lindau disease suggest pheochromocytoma. Ann Intern Med 120 6 (1994) 485-487
112. Telenius-Berg M., Ponder M.A., Berg B., et al. Quality of life after bilateral adrenalectomy in MEN 2. Henry Ford Hosp Med J 37 3-4 (1989) 160-163
113. Walther M.M., Keiser H.R., Choyke P.L., et al. Management of hereditary pheochromocytoma in von Hippel-Lindau kindreds with partial adrenalectomy. J Urol 161 2 (1999) 395-398
114. Meyer J.S., Roth L.M., and Silverman J.L. Papillary cystadenomas of the epididymis and spermatic cord. Cancer 17 (1964) 1241-1247
115. Price Jr. E.B. Papillary cystadenoma of the epididymis. A clinicopathologic analysis of 20 cases. Arch Pathol 91 5 (1971) 456-470